Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Biosimilar Rituximab Approved in Europe for Non-Hodgkin Lymphoma

June 20th 2017

The European Commission has approved the rituximab (Rituxan) biosimilar Rixathon (GP2013) to treat patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.

Dr. Abramson on TRANSCEND on JCAR017 Therapy in NHL

June 19th 2017

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the TRANSCEND study, which is exploring the CD19-directed chimeric antigen receptor (CAR) T-cell therapy JCAR017 in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

JCAR017 Impresses in Updated DLBCL Data

June 17th 2017

Treatment with JCAR017 demonstrated a complete response rate of 59% and an objective response rate of 86% for patients with relapsed or refractory diffuse large B-cell lymphoma.

Pembrolizumab Plus Rituximab Promising in Follicular Lymphoma

June 17th 2017

Combining pembrolizumab with rituximab induced a high response rate in patients with relapsed follicular lymphoma.

Copanlisib Lymphoma Data Updated as FDA Considers Approval

June 17th 2017

Copanlisib showed an objective response rate of 59.2% without inducing major colitis events or elevation of hepatic transaminases in patients with relapsed or refractory indolent B-cell lymphoma.

Obinutuzumab Benefit in Frontline Follicular Lymphoma Sustained With Longer Follow-Up

June 17th 2017

At more than 40 months’ follow-up, combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 32% versus rituximab plus chemotherapy in patients with follicular lymphoma.

BGB-3111 Plus Obinutuzumab Effective in CLL and Follicular Lymphoma

June 17th 2017

Combining the novel BTK inhibitor BGB-3111 with the CD-20 antibody obinutuzumab demonstrated clinical activity and was well tolerated in patients with chronic lymphocytic leukemia/small lymphocytic leukemia or follicular lymphoma.

Dr. Berinstein on Combination Treatments for High-Risk and Recurrent Follicular Lymphoma

June 16th 2017

Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.

Two Late-Stage Trials Test Novel PI3K Inhibitor in Non-Hodgkin Lymphoma

June 16th 2017

Copanlisib (BAY 80-6946), a novel PI3K inhibitor, is being combined with standard rituximab-based regimens in patients with relapsed, indolent non-Hodgkin lymphoma.

Combination of Ibrutinib and Buparlisib Shows Promise in MCL and other NHLs

June 16th 2017

Connie Batlevi, MD, PhD, discusses the combination of ibrutinib and buparlisib in MCL.

Tazemetostat Active in Follicular Lymphoma, DLBCL

June 16th 2017

Tazemetostat (EPZ-6438) demonstrated strong clinical activity in patients with advanced EZH2-mutated follicular lymphoma, and was also active in patients with diffuse large B-cell lymphoma.

5-Year Follow-Up Confirms Efficacy of Frontline Bendamustine Plus Rituximab in MCL, iNHL

June 15th 2017

Ian W. Flinn, MD, PhD, discusses the 5-year update of the BRIGHT study in MCL and NHL.

Dr. Nastoupil on Pembrolizumab Plus Rituximab in Relapsed Follicular Lymphoma

June 15th 2017

Loretta J. Nastoupil, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses high response rates with prembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Dr. Neelapu on Axi-Cel in the ZUMA-1 Trial for Refractory Aggressive Non-Hodgkin Lymphoma

June 15th 2017

Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; KTE-C19) for patients with refractory aggressive non-Hodgkin lymphoma.

Novel Regimens Explored for Rare DLBCL Subtypes

June 15th 2017

Sarah Rutherford, MD, discusses rare DLBCL subtypes, ongoing research to improve outcomes for these patient populations, and the potential role of CAR T-cell therapy.

Axicabtagene Ciloleucel NHL Data Presented as FDA Weighs Approval

June 15th 2017

Patients with refractory aggressive non-Hodgkin lymphoma lacking curative treatment options demonstrated high response rates and durable responses plus a manageable safety profile following treatment with axicabtagene ciloleucel.

Tisagenlecleucel-T Highly Active, With Durable Responses in DLBCL

June 14th 2017

Tisagenlecleucel-T (CTL019) met its primary endpoint for best objective response rate in patients with relapsed or refractory diffuse large B-cell lymphoma.

Dr. Kahl on ADCT-402 for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 14th 2017

Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.

FDA Grants Priority Review to KTE-C19 for Non-Hodgkin Lymphoma

May 26th 2017

The FDA has granted a priority review to axicabtagene ciloleucel for transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma.

Dual Expression of MYC, BCL2 Associated With Poorer Outcomes in DLBCL

May 26th 2017

Researchers using cell-of-origin classification connected dual expression of the proteins MYC and BCL2 with poorer survival in patients undergoing chemotherapy for diffuse large B-cell lymphoma.